Heat-shock protein 90 inhibitors: Will they ever succeed as chemotherapeutics?

Future Medicinal Chemistry

Volumn 7, Issue 2, 2015, Pages 87-90

  Wang, Yao ^a   Mcalpine, Shelli R ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

C terminal; heat shock protein; heat shock protein 90 chaperones; heat shock response; Hsp90 inhibitors; Hsp90 modulators; stress

Indexed keywords

HEAT SHOCK PROTEIN 90 INHIBITOR; ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 90;

CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM; NEOPLASMS; PATHOLOGY; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84923213030     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.154     Document Type: Review

References (21)

1. Morimoto RI, Tissieres A, Georgopoulois C. The stress response, function of the proteins and perspectives. In: Stress protein in biology and medicine. Morimoto RI, Tissieres A, Georgopoulos C (Eds). Cold Spring Harbor Laboratory Press, NY, USA, 1-36 (1990).
2. Anckar J, Sistonen L. Regulation of HSF1 in the heat stress response: implications in aging and disease. Annu. Rev. Biochem. 80, 1089-1115 (2011).
3. U.S. National Institutes of Health. www.clinicaltrials.gov
4. Modi S, Saura C, Henderson C et al. A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. Breast Cancer Res. Treat. 139, 107-113 (2013).
5. Gandhi N, Wild AT, Chettiar ST et al. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells. Cancer Biol. Ther. 14, 347-356 (2013).
6. McConnell JR, McAlpine SR. Heat shock proteins 27, 40, and 70 as combinational therapeutic targets. Bioorg. Med. Chem. Lett. 23, 1923-1928 (2013).
7. Morimoto RI. Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. Genes Dev. 12, 3788-3796 (1998).
8. Wang Y, Mcalpine SR. N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes. Chem. Comm. doi:10.1039/C1034CC07284G (2014) (In Press).
9. McConnell JM, Alexander LD, McAlpine SR. A heat shock protein inhibitor that modulates immunophilins and regulates hormone receptors. Bioorg. Med. Chem. Lett. 24, 661-666 (2014).
10. Koay YC, McConnell JR, Wang Y, Kim SJ, McAlpine SR. Chemically accessible Hsp90 inhibitor that does not induce a heat shock response. ACS Med. Chem. Lett. 5, 771-776 (2014).
11. Eskew JD, Sadikot T, Morales P et al. Development and characeterizatrion of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. Bio. Med. Central Cancer 11, 468 (2011).
12. Kim YSA, Lee S, Lee M-J et al. Update on Hsp90 inhibitors in clinical trials. Curr. Top. Med. Chem. 9, 1479-1492 (2009).
13. Sellers RP, Alexander LD, Johnson VA et al. A third generation of Sansalvamide A derivatives: design and synthesis of Hsp90 inhibitors. Bioorg. Med. Chem. 18, 6822-6856 (2010).
14. Kusuma BRZ, Sundstrom T, Peterson LB, Dobrowsky RT, Blagg BS. Synthesis and evaluation of novologues as C-Terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity. J. Med. Chem. 55, 5797-5812 (2012).
15. Centenera MM, Fitzpatrick AK, Tilley WD, Butler LM. Hsp90: still a viable target in prostate cancer. Biochim. Biophys. Acta 1835(2), 211-218 (2013).
16. Yamaki H, Suzuki H, Choi EC, Tanaka N. Inhibition of DNA synthesis in murine tumor cells by geldanamycin, an antibiotic of the benzoquinoid ansamycin group. J. Antibiot. (Tokyo) 35, 886-892 (1982).
17. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet Clin. Cancer Res. 18, 64-76 (2012).
18. Grem JL, Morrison G, Guo XD et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J. Clin. Oncol. 23, 1885-1893 (2005).
19. Ramsey DM, Kitson RRA, Levin JI, Moody CJ, McAlpine SR. Recent advances in macrocyclic Hsp90 inhibitors. In: Macrocycles in Drug Discovery. Levin JI (Ed.). RSC Books, London, UK, 37-77 (2014).
20. Goldman JW, Raju RN, Gordon GA et al. A first in human, safety, pharmacokinetics, and clinical activity Phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer 13, 152-161 (2013).
21. Kamal A, Thao L, Sensintaffar J et al. A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors. Nature 425, 407 (2003).